How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Energy and Power · Forecast 2027–2033
Renal Disease Market
- By Disease Type: Chronic Kidney Disease (CKD), Acute Kidney Injury (AKI), End-Stage Renal Disease (ESRD), Polycystic Kidney Disease (PKD), Glomerulonephritis
- By Treatment Modality: Hemodialysis, Peritoneal Dialysis, Kidney Transplantation, Conservative Management, Pharmacological Therapy
- By Therapeutic Class: Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, Immunosuppressants, Antihypertensives, Diuretics
- By Patient Population: Pediatric Patients, Adult Patients, Geriatric Patients
- By End-User: Hospitals, Dialysis Centers, Specialty Clinics, Home Care Settings
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Chronic Kidney Disease (CKD) leads By Disease Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 303 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.181 →
- 12 Company Profiles 17 players: SWOT & benchmarking p.189 →
Full report · locked preview
Everything inside the Renal Disease Market report
A complete, evidence-based study - 12 chapters and 127 sections covering market size, segmentation across 5 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Disease Type 5
Treatment Modality 5
Therapeutic Class 5
Patient Population 3
End-User 4
Companies profiled
Fresenius Medical Care AG & Co. KGaA
DaVita Inc.
Baxter International Inc.
B. Braun Melsungen AG
Nipro Corporation
AngioDynamics Inc.
Medtronic plc
NxStage Medical
Inc. (a division of Fresenius)
Asahi Kasei Corporation
Gambro (a part of Baxter)
Hospira
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Fresenius Medical Care AG & Co. KGaA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →DaVita Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Baxter International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →B. Braun Melsungen AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Nipro Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →AngioDynamics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →NxStage Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Inc. (a division of Fresenius)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Asahi Kasei Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Gambro (a part of Baxter)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Hospira
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Inc. (a Pfizer company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Terumo Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Outset Medical Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Renalytix AI
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,904M by 2033 · 5.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Chronic Kidney Disease (CKD)48.4
- Acute Kidney Injury (AKI)14.6
- End-Stage Renal Disease (ESRD)15.4
- Polycystic Kidney Disease (PKD)10.4
- Glomerulonephritis11.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$417.0M → $570.0M · 4.0%
Europe$290.6M → $421.7M · 4.8%
Asia Pacific$265.4M → $376.4M · 4.5%
Latin America$164.3M → $230.3M · 4.3%
Middle East and Africa$126.4M → $212.2M · 6.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.212026
5.222027
5.232028
5.252029
5.252030
5.272031
5.282032
5.302033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Fresenius Medical Care AG & Co. KGaA19.4
- DaVita Inc.20.6
- Baxter International Inc.6.2
- B. Braun Melsungen AG7.9
- Nipro Corporation9.7
- AngioDynamics Inc.8.2
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Disease Type8.6%
Treatment Modality20.8%
Therapeutic Class22.0%
Patient Population26.8%
End-User21.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.5
- Europe23.3
- Asia Pacific20.8
- Latin America12.7
- Middle East and Africa11.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Fresenius Medical Care AG & Co. KGaA | 97 | 75 | 98 | 74 | 85 | 89 | 86 |
| DaVita Inc. | 72 | 80 | 85 | 91 | 73 | 76 | 80 |
| Baxter International Inc. | 85 | 84 | 63 | 64 | 81 | 68 | 74 |
| B. Braun Melsungen AG | 69 | 81 | 77 | 59 | 57 | 69 | 69 |
| Nipro Corporation | 53 | 62 | 74 | 69 | 76 | 69 | 67 |
| AngioDynamics Inc. | 59 | 57 | 46 | 56 | 53 | 57 | 55 |
| Medtronic plc | 65 | 51 | 55 | 40 | 42 | 44 | 50 |
| NxStage Medical | 36 | 40 | 42 | 53 | 53 | 54 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Fresenius Medical Care AG & Co. KGaA
- DaVita Inc.
- Baxter International Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Fresenius Medical Care AG & Co. KGaA | ◐ | ✓ | ✓ | ✓ | ◐ | ✓ |
| DaVita Inc. | ✓ | ◐ | ◐ | ✓ | ◐ | ✓ |
| Baxter International Inc. | ✓ | ◐ | ✓ | ◐ | ◐ | ◐ |
| B. Braun Melsungen AG | ✓ | ✓ | ◐ | − | ◐ | ◐ |
| Nipro Corporation | − | ◐ | ◐ | ◐ | ◐ | ◐ |
| AngioDynamics Inc. | ◐ | ◐ | ◐ | ◐ | − | − |
| Medtronic plc | ✓ | − | − | − | − | ◐ |
| NxStage Medical | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Fresenius Medical Care AG & Co. KGaA86
2DaVita Inc.80
3Baxter International Inc.74
4B. Braun Melsungen AG69
5Nipro Corporation67
6AngioDynamics Inc.55
7Medtronic plc50
8NxStage Medical46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Fresenius Medical Care AG & Co. KGaADaVita Inc.
Challenger3
Strong scale, closing on the leaders.
Baxter International Inc.B. Braun Melsungen AGNipro Corporation
Niche3
Specialists in a single segment or region.
AngioDynamics Inc.Medtronic plcNxStage Medical
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Disease Type in North America, then scale across Renal Disease Market — a $689M beachhead inside a $9.42B market.
Beachhead (SOM)$689Mobtainable near-term
Serviceable (SAM)$3.95Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Chronic Kidney Disease (CKD)
Best fit — highest urgency & budget in Disease Type.
Economic buyer78 fit
Acute Kidney Injury (AKI)
Strong fit — clear ROI and a fast path to value.
End user67 fit
End-Stage Renal Disease (ESRD)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Disease Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Modality & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Therapeutic Class
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel27%
Digital / self-serve20%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Disease Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Renal Disease Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified20%
Evaluation12%
Closed-won6%
$16.4KCAC
$84KLTV
5.1:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Renal Disease Market is a high-growth opportunity — $12.4B by 2033, compounding at 11.1%.
TAM · 2025$5.34Btoday
TAM · 2033$12.4Bforecast
CAGR11.1%2027–2033
Cumulative$76.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$12.4BTotal addressable market
SAM$4.67BServiceable available market
SOM$852MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.1% CAGR
Demand compounds through 2033, outpacing GDP across Disease Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Disease Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$12.4BLarge & growingTAM by 2033 at 11.1% CAGR
$4.67BServiceable nowreachable with today’s model
$852MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$9.69BBear7.2% CAGR
$12.4BBase11.1% CAGR
$15.9BBull14.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Modality optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Renal Disease Market — a $5.59B market by 2033. Plan: grow share from 10.6% to 17.0%.
Market size · 2033$5.59Btotal addressable
Market CAGR8.0%2027–2033
Target share17.0%from 10.6% today
Revenue ambition$951Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.6% | 17.0% | On track |
| Revenue | $570M | $951M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 32.0% | 41.2% | On track |
| Customer retention | 85.2% | 92.5% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Disease Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Treatment Modality capability
A defensible second engine — invest in Treatment Modality to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Disease Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Modality
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $113M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Modality
- Authorise North America expansion plan
- Fund R&D program for Disease Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Renal Disease Market conversation — a $9.76B market you can size, segment and defend in minutes.
Market size · 2033$9.76Btotal opportunity
Growth7.3%CAGR to 2033
Addressable buyers1,562+accounts in scope
Typical ROI4.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Disease Type
Goal Grow share in Disease Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.4×return on cost, year one
< 3 mopayback period
$91K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Fresenius Medical Care AG & Co. KGaADaVita Inc.Baxter International Inc.B. Braun Melsungen AGNipro CorporationAngioDynamics Inc.Medtronic plcNxStage Medical+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Renal Disease Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Renal Disease Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Energy and Power · scroll →Automatic Bypass Valve Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportAutomatic Boiler Bottom Blowdown Systems Market
Market size, share, segmentation and regional forecast.
$605M market · 2025 base year
View reportAutomatic Biomass Briquetting Machine Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportAutomatic Battery Testing System Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportAutomatic Battery Production Line Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportAutomatic Artificial Lift Device Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportAutomated Testing System for Energy Storage Inverters Market
Market size, share, segmentation and regional forecast.
$842M market · 2025 base year
View reportAutomated Power Generation Dispatch Software Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportAutomated Operation Fuel Cell Testing Equipment Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportAutomated Oil Analyzer Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportAutomated Lithium Battery Slurry Preparation System Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportAutomated Harmonic Generator Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.